PROSTIN VR

This brand name is authorized in United States. It is also authorized in Canada, Croatia, Estonia, Hong Kong SAR China, Israel, Malta, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, UK.

Active ingredients

The drug PROSTIN VR contains one active pharmaceutical ingredient (API):

1	Alprostadil UNII F5TD010360 - ALPROSTADIL
	Alprostadil is chemically identical to prostaglandin E1, the actions of which include vasodilatation of blood vessels in the erectile tissues of the corpora cavernosa and increase in cavernosal artery blood flow, causing penile rigidity.
	Read more about Alprostadil

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PROSTIN VR Concentrate for solution for infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C01EA01	Alprostadil	C Cardiovascular system → C01 Cardiac therapy → C01E Other cardiac preparations → C01EA Prostaglandins
Discover more medicines within C01EA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	00559253
EE	Ravimiamet	1692299, 1758382, 1759091
GB	Medicines & Healthcare Products Regulatory Agency	47462
HK	Department of Health Drug Office	22532
HR	Agencija za lijekove i medicinske proizvode	HR-H-396564180
IL	מִשְׂרַד הַבְּרִיאוּת	8925
MT	Medicines Authority	AA565/55401, AA565/55403
NL	Z-Index G-Standaard, PRK	70165
NZ	Medicines and Medical Devices Safety Authority	3473
PL	Rejestru Produktów Leczniczych	100056144
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67256001
SG	Health Sciences Authority	02280P
US	FDA, National Drug Code	0009-3169
ZA	Health Products Regulatory Authority	Q/7.1/32